What's Happening?
Merck Animal Health has announced the commercial availability of Circumvent CL, a new vaccine designed to protect pigs aged three weeks and older against Porcine Circovirus Types 2a and 2d, as well as Lawsonia
intracellularis. This addition to Merck's swine health portfolio aims to simplify herd health programs by offering a ready-to-use vaccine that does not require mixing or reconstitution, thereby reducing preparation time and minimizing handling errors. Circumvent CL complements the existing Circumvent vaccine family, which includes Circumvent CML, a vaccine that also protects against Mycoplasma hyopneumoniae. The new vaccine is particularly beneficial for herds that do not require mycoplasma vaccination, providing targeted protection against circovirus and Lawsonia. Available in 50 and 250 dose presentations, a 500-dose option is expected in early 2026.
Why It's Important?
The introduction of Circumvent CL is significant for the swine industry as it offers a streamlined approach to disease prevention, which is crucial for maintaining herd health and productivity. By simplifying the vaccination process, Merck's new product can help reduce labor costs and improve the efficiency of swine operations. This development is particularly important for producers looking to optimize their herd health strategies without unnecessary components, potentially leading to better economic outcomes. The vaccine's ease of use and dual disease protection make it a valuable tool for veterinarians and producers aiming to protect against significant enteric and systemic diseases in swine.
What's Next?
Merck plans to expand the availability of Circumvent CL with a 500-dose option in the first quarter of 2026. As the product becomes more widely available, it is likely that more swine producers will adopt this vaccine as part of their herd health management strategies. The company will continue to provide information and support through its representatives and official resources, ensuring that producers can effectively integrate this new vaccine into their operations.
